Condition

Anaplastic Oligodendroglioma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions7

Lead sponsors shown3

Clinical trials

3 shown

Pediatric Long-Term Follow-up and Rollover StudyNCT03975829 · 2019-11-04

ACTIVE_NOT_RECRUITING

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsNCT01522820 · 2012-03-01

COMPLETED

Expanded Access to ANG1005 for Individual PatientsNCT02755987

NO_LONGER_AVAILABLE

Common interventions

ANG1005DRUG1 dabrafenibDRUG1 DEC-205/NY-ESO-1 Fusion Protein CDX-1401BIOLOGICAL1 Laboratory Biomarker AnalysisOTHER1 Pharmacological StudyOTHER1 SirolimusDRUG1 trametinibDRUG1

Leading sponsors

Angiochem Inc 1 Novartis Pharmaceuticals 1 Roswell Park Cancer Institute 1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

NO_LONGER_AVAILABLE1

Phase mix

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.